Medicus Pharma announces phase 2 study SKNJCT-003 underway

Medicus Pharma (MDCX) announces that its phase 2 clinical study, SKNJCT-003, which is currently underway in nine clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study. The Company also announced that it is on track to complete an interim data analysis before the end of Q1 2025 and to submit its findings to the United States Food and Drug Administration as part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and gain further alignment on the clinical pathway. The Company’s aim is to gain FDA’s consent to fast-track the clinical development program.